SeaStar Medical (NASDAQ:ICU – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for SeaStar Medical and Organon & Co., as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SeaStar Medical | 1 | 0 | 0 | 0 | 1.00 |
| Organon & Co. | 5 | 1 | 0 | 1 | 1.57 |
SeaStar Medical currently has a consensus price target of $6.00, suggesting a potential upside of 117.39%. Organon & Co. has a consensus price target of $8.50, suggesting a potential upside of 16.36%. Given SeaStar Medical’s higher probable upside, equities analysts clearly believe SeaStar Medical is more favorable than Organon & Co..
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SeaStar Medical | $140,000.00 | 74.72 | -$24.83 million | ($16.50) | -0.17 |
| Organon & Co. | $6.22 billion | 0.31 | $187.00 million | $0.71 | 10.29 |
Organon & Co. has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
SeaStar Medical has a beta of -1, indicating that its share price is 200% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Profitability
This table compares SeaStar Medical and Organon & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SeaStar Medical | -1,551.08% | -414.50% | -151.13% |
| Organon & Co. | 3.01% | 122.01% | 6.74% |
Institutional & Insider Ownership
1.7% of SeaStar Medical shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 0.7% of SeaStar Medical shares are held by company insiders. Comparatively, 2.0% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Organon & Co. beats SeaStar Medical on 12 of the 14 factors compared between the two stocks.
About SeaStar Medical
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
